Regina Eiselt

TL;DR: Investigation of the expression of CYP3A5 and its genetic determinants in a panel of 183 Caucasian liver samples reports that a SNP within intron 3 (g.6986G>A) is the primary cause of the CYP4A5 protein polymorphism, and should add to efforts to identify clinically relevant, CYP2A5-specific reactions and to further elucidate traits responsible for variable expression of the entire CYP 3A family.

TL;DR: The identification of a new member of the CYP3A family and the characterization of the full CYP 3A locus will aid efforts to identify the genetic variants underlying its variable expression, which will lead to a better optimization of therapies involving the numerous substrates of CYP2A proteins.

TL;DR: A study of 213 Middle and Western European DNA samples resulted in the identification of 18 new CYP3A4 variants, including eight protein variants that may play a role in the atypical response to drugs or altered sensitivity to carcinogens.

TL;DR: Three natural PXR protein variants may play a role in the observed interindividual variability of CYP3A4 expression and may be involved in rare, atypical responses to drugs or altered sensitivities to carcinogens.

TL;DR: In this paper, the authors proposed a method for identifying and obtaining drug candidates and inhibitors for therapy of disorders related to the malfunction of the CYP3AX genes as well as to methods of diagnosing the status of such disorders.